Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?

LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.

Zacks Investment Research • Oct 28, 2026

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?

Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments

New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?

Newsfile Corp • Oct 21, 2026

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.

24/7 Wall Street • Oct 14, 2026

Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed

Liquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.

Investors Business Daily • Oct 14, 2026

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.

Barrons • Oct 14, 2026

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.

Proactive Investors • Oct 14, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.

Zacks Investment Research • Oct 14, 2026

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.

GlobeNewsWire • Oct 13, 2026

Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.

PRNewsWire • Oct 12, 2026